tiprankstipranks
Avenue Therapeutics Inc (ATXI)
NASDAQ:ATXI
Holding ATXI?
Track your performance easily

Avenue Therapeutics (ATXI) Income Statement

314 Followers

Avenue Therapeutics Income Statement

Last quarter (Q3 2024), Avenue Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Avenue Therapeutics's net income was $-3.08M. See Avenue Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.62M$ 14.54M$ 8.04M$ 3.74M$ 5.21M$ 26.27M
Operating Income
$ -11.81M$ -14.54M$ -8.04M$ -3.74M$ -5.21M$ -26.27M
Net Non Operating Interest Income Expense
$ 255.00K$ 206.00K$ 1.14M$ 7.00K$ 62.00K$ 357.00K
Other Income Expense
$ 5.64M$ 4.26M$ 5.58M---
Pretax Income
$ -5.91M$ -10.49M$ -3.60M$ -3.73M$ -5.15M$ -25.91M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -13.96M$ -10.38M$ -3.55M$ -3.73M$ -5.15M$ -25.91M
Basic EPS
$ -22.92$ -0.98-$ -3.30$ -348.75-
Diluted EPS
$ -22.92$ -0.98-$ -3.30$ -348.75$ -24.75
Basic Average Shares
$ 24.21M$ 10.59M$ 29.14K$ 1.13M$ 14.67K$ 1.05M
Diluted Average Shares
$ 24.12M$ 10.59M$ 29.14K$ 1.13M$ 14.67K$ 1.05M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 4.39M$ 14.54M$ 8.04M$ 3.74M$ 5.21M$ 26.27M
Net Income From Continuing And Discontinued Operation
$ -9.47M$ -10.38M$ -3.55M$ -3.73M$ -5.15M$ -25.91M
Normalized Income
$ -4.80M$ -1.34M----
Interest Expense
------
EBIT
$ -1.34M$ -10.16M$ -2.44M$ -3.73M$ -5.21M$ -25.91M
EBITDA
$ -1.34M$ -10.16M$ -2.44M$ -3.73M$ -5.21M$ -25.91M
Currency in USD

Avenue Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis